BNTX - BioNTech SE logo

BioNTech SE

BNTX

BioNTech SE develops and commercializes immunotherapies and vaccines, focusing on mRNA technology for cancer treatment and infectious diseases, including SARS-CoV-2. Its pipeline includes oncology drugs in various clinical trial phases targeting multiple cancers.

⚕️ Healthcare NASDAQ Listed 2019 € EUR
$1,000 invested 5 years ago →$326today

Score Overview

1 Year
Score
Net Growth-55.08%
Net TrendShrank
Net Income Consistency—
Rev Growth-4.11%
Rev TrendShrank
Revenue Consistency—
5 Years
Score1.2
Net Growth-116.44%
Net TrendNever
Net Income Consistency—
Rev Growth-86.07%
Rev Trend20%
Revenue Consistency—
All Time
Score—
Net Growth-7x
Net TrendNever
Net Income Consistency
Rev Growth—
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where BioNTech SE has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BNTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 89.67—
1 Year2025-10-22
$ 106.23-15.59%
5 Years2021-10-22
$ 274.70-67.36%
All Time2019-10-10
$ 14.056x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 2.64B-€ 1.69B€ 9.73B
2025€ 2.75B-€ 1.09B€ 14.83B
2024€ 2.75B-€ 665M€ 16.78B
2023€ 3.81B€ 930M€ 16.54B
2022€ 17.31B€ 9.43B€ 14.06B
2021€ 18.97B€ 10.29B€ 2.07B
2020€ 482M€ 1.34B
IPO2019-€ 179M€ 520M
BNTX - BioNTech SE logo

BioNTech SE fundamental performance

Between 2020 and 2025, revenue grew from € 482M to € 2.75B. Revenue increased in 1 of those 5 years; net income in 0.

BioNTech SE currently holds a 5-year HDB Score of 1.2 out of 10. How the HDB Score is calculated.

Membership

Explore BNTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies